Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 5, 2024
Daily News
December 5, 2024
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- LDP Lawmakers Continue Call to Abolish Off-Year Scheme
December 5, 2024
- Takeda Bags Rights to Keros Therapeutics’ Elritercept
December 5, 2024
- Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
- DPP Submits Request to MOF for Scrapping Off-Year Revisions
December 5, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…